Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Metformin Suppresses SARS-CoV-2 in Cell Culture
Parthasarathy et al., bioRxiv, doi:10.1101/2021.11.18.469078 (Preprint) (In Vitro)
Parthasarathy et al., Metformin Suppresses SARS-CoV-2 in Cell Culture, bioRxiv, doi:10.1101/2021.11.18.469078 (Preprint) (In Vitro)
Nov 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
In Vitro study showing metformin inhibits SARS-CoV-2 in Caco2 cells. Metformin reduced viral titers by nearly 99%, and by about 90% when cells were treated prior to infection.
Parthasarathy et al., 19 Nov 2021, preprint, 3 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: bioRxiv preprint doi: https://doi.org/10.1101/2021.11.18.469078; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Metformin Suppresses SARS-CoV-2 in Cell Culture 2 3 Haripriya Parthasarathy1, Dixit Tandel1,2, and Krishnan H. Harshan1,2,€ 4 5 1 CSIR-Centre for Cellular and Molecular Biology, Hyderabad, India 500007 6 2 Academy for Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India 7 8 € Correspondence: hkrishnan@ccmb.res.in 9 10 Keywords 11 SARS-CoV-2, COVID-19, anti-viral activity, Metformin, AMPK, Diabetes 12 13 14 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.11.18.469078; this version posted November 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 15 ABSTRACT 16 People with diabetes are reported to have a higher risk of experiencing severe 17 COVID-19 complications. Metformin, a first-line medication for type 2 diabetes, has 18 antiviral properties. Some studies have indicated its prognostic potential in COVID- 19 19. Here, we report that metformin significantly inhibits SARS-CoV-2 growth in cell 20 culture models. SARS-CoV-2 infection of gut epithelial cell line, Caco2, resulted in 21 higher phosphorylation of AMPK. Metformin reduced viral titers in the infected cells 22 by nearly 99%, and by about 90% when cells were treated prior to infection. 23 Metformin pre-treatment resulted in further phosphorylation of AMPK and caused a 24 ten-fold reduction of viral titers indicating its potential in preventing naïve infections. 25 Confirming the positive impact of AMPK activation, another AMPK activator AICAR 26 substantially inhibited of viral titers and, AMPK inhibitor Compound C, augmented it 27 considerably. Metformin treatment post-SARS-CoV-2 infection resulted in nearly 28 hundred-fold reduction of viral titers, indicating that the antiviral potency of the drug 29 is far higher in infected cells, while still being able to reduce fresh infection. 30 Metformin displayed SARS-CoV-2 TCID50 and TCID90 at 3.5 and 8.9 mM, 31 respectively. In conclusion, our study demonstrates that metformin is very effective in 32 limiting the replication of SARS-CoV-2 in cell culture and thus possibly could offer 33 double benefits to diabetic COVID-19 patients by lowering both blood glucose levels 34 and viral load.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit